[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11202005781WA - Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof - Google Patents

Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof

Info

Publication number
SG11202005781WA
SG11202005781WA SG11202005781WA SG11202005781WA SG11202005781WA SG 11202005781W A SG11202005781W A SG 11202005781WA SG 11202005781W A SG11202005781W A SG 11202005781WA SG 11202005781W A SG11202005781W A SG 11202005781WA SG 11202005781W A SG11202005781W A SG 11202005781WA
Authority
SG
Singapore
Prior art keywords
cerdulatinib
pharmaceutical compositions
topical skin
containing topical
skin pharmaceutical
Prior art date
Application number
SG11202005781WA
Inventor
Charles Evans
Cameron Stevenson
Marc Brown
Original Assignee
Dermavant Sciences GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dermavant Sciences GmbH filed Critical Dermavant Sciences GmbH
Publication of SG11202005781WA publication Critical patent/SG11202005781WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202005781WA 2018-01-09 2019-01-09 Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof SG11202005781WA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862615261P 2018-01-09 2018-01-09
US201862686509P 2018-06-18 2018-06-18
US201862765133P 2018-08-16 2018-08-16
US201862772415P 2018-11-28 2018-11-28
PCT/IB2019/000017 WO2019138291A2 (en) 2018-01-09 2019-01-09 Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof

Publications (1)

Publication Number Publication Date
SG11202005781WA true SG11202005781WA (en) 2020-07-29

Family

ID=65685834

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005781WA SG11202005781WA (en) 2018-01-09 2019-01-09 Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof

Country Status (17)

Country Link
US (1) US20200390689A1 (en)
EP (1) EP3737354A2 (en)
JP (1) JP2021510159A (en)
KR (1) KR20200108297A (en)
CN (1) CN111818910A (en)
AU (1) AU2019208049A1 (en)
BR (1) BR112020013976A2 (en)
CA (1) CA3087124A1 (en)
CL (1) CL2020001791A1 (en)
CO (1) CO2020008244A2 (en)
IL (1) IL275899A (en)
MX (1) MX2020007062A (en)
RU (1) RU2020124293A (en)
SG (1) SG11202005781WA (en)
TW (1) TW201938167A (en)
WO (1) WO2019138291A2 (en)
ZA (1) ZA202004104B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019282155A1 (en) * 2018-06-04 2021-01-07 Lars BRICHTA Topical compositions for stimulating hair growth
WO2023225373A1 (en) * 2022-05-20 2023-11-23 Dermbiont, Inc. Compositions and formulations for use of a pk inhibitor for the prevention, treatment, and improvement of skin diseases, conditions, and disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2490888C (en) 2002-06-28 2011-05-24 Yamanouchi Pharmaceutical Co., Ltd. Diaminopyrimidinecarboxamide derivative
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CA2799928C (en) * 2010-05-21 2020-03-31 Incyte Corporation Topical formulation for a jak inhibitor
SG193245A1 (en) * 2011-04-08 2013-10-30 Pfizer Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
CA2857189A1 (en) * 2011-12-08 2013-06-13 Rigel Pharmaceuticals, Inc. Topical formulation for administering a compound
CA2985185A1 (en) * 2015-05-07 2016-11-10 The Trustees Of Columbia University In The City Of New York Methods and compositions for promoting hair growth
EP3334432B1 (en) * 2015-08-12 2022-02-23 Portola Pharmaceuticals, Inc. Cerdulatinib for treating myeloma
EP3383396B1 (en) * 2015-12-04 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma
BR112018075202A2 (en) * 2016-06-07 2019-03-19 Dermavant Sciences GmbH Topical formulation and method of treating a dermatological condition in a subject
US11957931B2 (en) * 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo

Also Published As

Publication number Publication date
AU2019208049A1 (en) 2020-07-23
CN111818910A (en) 2020-10-23
TW201938167A (en) 2019-10-01
MX2020007062A (en) 2021-03-09
ZA202004104B (en) 2022-01-26
JP2021510159A (en) 2021-04-15
KR20200108297A (en) 2020-09-17
CL2020001791A1 (en) 2020-12-04
CA3087124A1 (en) 2019-07-18
US20200390689A1 (en) 2020-12-17
WO2019138291A3 (en) 2019-08-22
EP3737354A2 (en) 2020-11-18
CO2020008244A2 (en) 2020-10-30
WO2019138291A2 (en) 2019-07-18
BR112020013976A2 (en) 2020-12-08
IL275899A (en) 2020-08-31
RU2020124293A (en) 2022-02-10

Similar Documents

Publication Publication Date Title
HK1248526A1 (en) Cosmetic and topical compositions comprising cannabigerol
EP3706741A4 (en) Pharmaceutical composition and use thereof
EP3607957A4 (en) Pharmaceutical composition and cosmetic composition
ZA201904704B (en) Topical cyclosporine-containing formulations and uses thereof
EP3735258A4 (en) Topical skin care compositions
EP3434285A4 (en) Pharmaceutical composition and use thereof
HK1259228A1 (en) Two-phase cosmetic composition and use thereof for topical application
EP4074336A4 (en) Pharmaceutical composition and use thereof
HK1245631A1 (en) Hydroalcoholic extract of schinus molle, cosmetic compositions comprising the same and cosmetic uses thereof
GB2586731B (en) Topical skin care compositions
EP3823657C0 (en) Compositions for cosmetic and dermatological use
IL275899A (en) Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof
EP3302483A4 (en) Pharmaceutical compositions and use thereof
IL279877A (en) Ivosidenib forms and pharmaceutical compositions
EP3497080A4 (en) Pharmaceutical formulations and their use
IL261929B (en) Stable pharmaceutical compositions for topical administration and uses thereof
EP3615064A4 (en) Enriched cellular compositions and therapeutic use
ZA202100166B (en) Composition comprising glycyrrhin and cosmetic and pharmaceutical uses thereof
EP3269709A4 (en) N-phenyl-n'-phenoxycarbonyl-phenylsulfonhydrazide derivative and pharmaceutical composition comprising same
GB201905509D0 (en) Pharmaceutical compositions and associated lits and uses
EP3718543A4 (en) Pharmaceutical composition and use thereof
EP3664800A4 (en) Therapeutic formulations and uses thereof
PL3478260T3 (en) Skin care composition and use thereof
PT3177283T (en) Active compound and related composition for dermatological use in the pharmaceutical or cosmetic field
ZA202103782B (en) Teriflunomide topical pharmaceutical compositions